| Assessment Status | Rapid Review Complete |
| HTA ID | 22058 |
| Drug | Tucatinib |
| Brand | Tukysa® |
| Indication | In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
| Assessment Process | |
| Rapid review commissioned | 23/08/2022 |
| Rapid review completed | 20/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tucatinib compared with the current standard of care. |
